Imatinib was consequential to identification of a bcr-abl fusion protein resulting from specific chromosome translocation between chromosomes 9 and 22 in CML, whereas development of Herceptin followed the detection of recurrent HER/Neu (ErbB2) amplification on abnormal chromosomes in breast cancer cells (3,4). The gene discussed is ERBB2; the disease is breast carcinoma.